Genomics in Cancer Care Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Technology, By Application, By End User, By Region & Competition, 2021-2031F

Description

The Global Genomics in Cancer Care Market is projected for substantial growth, expanding from USD 16.79 Billion in 2025 to USD 42.94 Billion by 2031, at a robust 16.94% CAGR. This market focuses on analyzing patient and tumor genetic profiles to guide precision oncology through targeted therapies and personalized diagnostic strategies. Its expansion is fundamentally driven by the escalating global incidence of oncological diseases, demanding advanced diagnostic tools, alongside the continuous reduction in costs associated with next-generation sequencing (NGS) technologies. For instance, the American Cancer Society projects 2,041,910 new cancer cases in the United States in 2025, underscoring the critical need for genomic interventions. The declining costs of genome sequencing, propelled by advancements like the 352 NovaSeq X instruments shipped by Illumina in 2023, allow clinical laboratories to process samples more efficiently, thereby democratizing access to comprehensive genomic profiling. Complementing this, non-invasive liquid biopsy solutions are revolutionizing diagnostics by detecting circulating tumor DNA for early detection and monitoring, as demonstrated by Guardant Health's Shield test achieving 83% sensitivity for colorectal cancer detection. This accessibility is crucial given the World Health Organization's prediction of a 77% rise in new cancer cases to 35 million by 2050, highlighting the need for scalable screening tools.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 16.79 Billion
Market Size 2031	USD 42.94 Billion
CAGR 2026-2031	16.94%
Fastest Growing Segment	Personalized Medicine
Largest Market	North America

Market Driver

The continuous reduction in genome sequencing costs, driven by advancements in Next-Generation Sequencing (NGS) technologies, serves as a primary engine for market growth by enabling high-throughput sequencing platforms to process genetic samples with greater speed and efficiency. This democratizes access to comprehensive genomic profiling, as evidenced by Illumina's shipment of 352 NovaSeq X instruments during 2023, which significantly scaled up genomic sequencing capabilities for laboratories and reduced the barrier to entry for healthcare facilities to integrate complex genomic data into routine oncology workflows. Simultaneously, the emergence of non-invasive liquid biopsy solutions is reshaping clinical diagnostics by offering a viable alternative to traditional tissue biopsies, detecting circulating tumor DNA to identify genetic mutations and facilitate early detection and continuous monitoring of treatment response. According to Guardant Health, its FDA-approved Shield test demonstrated 83% sensitivity for colorectal cancer detection. This shift toward accessible testing is crucial as the global burden of disease intensifies, with new cancer cases predicted to rise by 77% to reach 35 million by 2050, as reported by the World Health Organization in 2024. Consequently, the scalability of liquid biopsies directly addresses the need for mass screening tools capable of managing this increasing patient population.

Market Challenge

Despite this strong growth trajectory, the market faces significant impediments, primarily the lack of standardized reimbursement policies and the high costs associated with comprehensive genomic profiling. Inconsistent payer coverage criteria create financial uncertainty for healthcare providers, often leading to hesitation in ordering advanced diagnostic tests, which limits the generation of essential genetic data and disrupts clinical workflows. This economic burden extends directly to patients, with high out-of-pocket expenses often forcing them to decline recommended profiling, as exemplified by more than 40% of cancer patients in the United States exhausting their life savings within two years of treatment, according to the American Association for Cancer Research. Consequently, patient access and adoption rates are reduced, stifling market expansion and potential revenue growth for genomic interventions in standard cancer care.

Market Trends

The market is simultaneously being shaped by transformative trends. The integration of artificial intelligence (AI) into genomic workflows is automating the analysis of vast datasets to identify actionable oncological biomarkers, thereby addressing manual variant curation bottlenecks and allowing researchers to efficiently correlate complex genetic profiles with therapeutic outcomes. This commercial traction is significant as laboratories seek to scale precision oncology operations, with Tempus AI reporting full-year revenue of $693.4 million in 2024, representing a 30.4% year-over-year increase driven by the widespread adoption of its AI-enabled genomics platform, highlighting the growing reliance on computational tools for enhanced diagnostic speed and accuracy. Concurrently, the emergence of long-read sequencing technologies is proving essential for detecting complex structural variants often missed by traditional short-read platforms. These systems sequence long DNA stretches without fragmentation, providing a more complete picture of tumor heterogeneity and fusion genes critical for targeted treatment planning. The rapid adoption of this technology is evident in Oxford Nanopore Technologies' PromethION product range, which experienced a 55.8% year-over-year revenue growth in 2024, indicating a strong market shift toward native long-read capabilities that empower clinicians to uncover comprehensive structural data vital for developing novel cancer therapies.

Key Market Players

Illumina Inc
Agilent Technologies, Inc.
Roche Diagnostics
Cancer Genetics, Inc.
Bio-Rad Laboratories Inc
Sigma-Aldrich Corp
QIAGEN NV
GE Healthcare Inc
Life Technologies Corp
Quest Diagnostics Inc

Report Scope

In this report, the Global Genomics in Cancer Care Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genomics in Cancer Care Market, By Product

Instruments
Consumables
Services

Genomics in Cancer Care Market, By Technology

Genome Sequencing
PCR
Microarray
Nucleic Acid Extraction and Purification
Others

Genomics in Cancer Care Market, By Application

Diagnostics
Personalized Medicine
Drug Discovery & Development
Research

Genomics in Cancer Care Market, By End User

Hospitals
Research Institutes & Academic Institutes
Others

Genomics in Cancer Care Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genomics in Cancer Care Market.

Available Customizations:

Global Genomics in Cancer Care Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genomics in Cancer Care Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Instruments, Consumables, Services)
- 5.2.2. By Technology (Genome Sequencing, PCR, Microarray, Nucleic Acid Extraction and Purification, Others)
- 5.2.3. By Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research)
- 5.2.4. By End User (Hospitals, Research Institutes & Academic Institutes, Others)
- 5.2.5. By Region
- 5.2.6. By Company (2025)
5.3. Market Map

6. North America Genomics in Cancer Care Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Technology
- 6.2.3. By Application
- 6.2.4. By End User
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Genomics in Cancer Care Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Technology
    - 6.3.1.2.3. By Application
    - 6.3.1.2.4. By End User
- 6.3.2. Canada Genomics in Cancer Care Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Technology
    - 6.3.2.2.3. By Application
    - 6.3.2.2.4. By End User
- 6.3.3. Mexico Genomics in Cancer Care Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Technology
    - 6.3.3.2.3. By Application
    - 6.3.3.2.4. By End User

7. Europe Genomics in Cancer Care Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Technology
- 7.2.3. By Application
- 7.2.4. By End User
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Genomics in Cancer Care Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Technology
    - 7.3.1.2.3. By Application
    - 7.3.1.2.4. By End User
- 7.3.2. France Genomics in Cancer Care Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Technology
    - 7.3.2.2.3. By Application
    - 7.3.2.2.4. By End User
- 7.3.3. United Kingdom Genomics in Cancer Care Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Technology
    - 7.3.3.2.3. By Application
    - 7.3.3.2.4. By End User
- 7.3.4. Italy Genomics in Cancer Care Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Technology
    - 7.3.4.2.3. By Application
    - 7.3.4.2.4. By End User
- 7.3.5. Spain Genomics in Cancer Care Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Technology
    - 7.3.5.2.3. By Application
    - 7.3.5.2.4. By End User

8. Asia Pacific Genomics in Cancer Care Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Technology
- 8.2.3. By Application
- 8.2.4. By End User
- 8.2.5. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Genomics in Cancer Care Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Technology
    - 8.3.1.2.3. By Application
    - 8.3.1.2.4. By End User
- 8.3.2. India Genomics in Cancer Care Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Technology
    - 8.3.2.2.3. By Application
    - 8.3.2.2.4. By End User
- 8.3.3. Japan Genomics in Cancer Care Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Technology
    - 8.3.3.2.3. By Application
    - 8.3.3.2.4. By End User
- 8.3.4. South Korea Genomics in Cancer Care Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Technology
    - 8.3.4.2.3. By Application
    - 8.3.4.2.4. By End User
- 8.3.5. Australia Genomics in Cancer Care Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Technology
    - 8.3.5.2.3. By Application
    - 8.3.5.2.4. By End User

9. Middle East & Africa Genomics in Cancer Care Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Technology
- 9.2.3. By Application
- 9.2.4. By End User
- 9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Genomics in Cancer Care Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Technology
    - 9.3.1.2.3. By Application
    - 9.3.1.2.4. By End User
- 9.3.2. UAE Genomics in Cancer Care Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Technology
    - 9.3.2.2.3. By Application
    - 9.3.2.2.4. By End User
- 9.3.3. South Africa Genomics in Cancer Care Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Technology
    - 9.3.3.2.3. By Application
    - 9.3.3.2.4. By End User

10. South America Genomics in Cancer Care Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Technology
- 10.2.3. By Application
- 10.2.4. By End User
- 10.2.5. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Genomics in Cancer Care Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Technology
    - 10.3.1.2.3. By Application
    - 10.3.1.2.4. By End User
- 10.3.2. Colombia Genomics in Cancer Care Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Technology
    - 10.3.2.2.3. By Application
    - 10.3.2.2.4. By End User
- 10.3.3. Argentina Genomics in Cancer Care Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Technology
    - 10.3.3.2.3. By Application
    - 10.3.3.2.4. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Genomics in Cancer Care Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Illumina Inc
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Agilent Technologies, Inc.
15.3. Roche Diagnostics
15.4. Cancer Genetics, Inc.
15.5. Bio-Rad Laboratories Inc
15.6. Sigma-Aldrich Corp
15.7. QIAGEN NV
15.8. GE Healthcare Inc
15.9. Life Technologies Corp
15.10. Quest Diagnostics Inc